Skip to Main Content



ABC News reports that pharmaceutical manufacturer Allergan pled guilty for its off-label promotion of Botox and will pay $600 million to settle additional charges in a longstanding federal investigation.

Botox is best known for its ability to smooth out wrinkles, but it is also approved to treat spasms in the neck, wrist and fingers, eye muscle disorders and excessive arm sweating.

Allergan released a statement Wednesday saying it would plead guilty to one misdemeanor charge of "misbranding" for marketing Botox as a treatment for unapproved uses such as for headache, pain and cerebral palsy in children.